Bottom line: Retatrutide may be the most powerful weight-loss drug tested so far
Compared with a group of people with a similar set of clinical characteristics matched closely on demographic factors such as age and ethnicity, treatment indicators such as average body mass index and diabetes prevalence, history of treatments such as bariatric surgery and prevalence of related comorbidities the analysis found that those on GLP-1s lost about twice as much weight
Comprehensive Support for GLP-1 Therapy Manage Side Effects &
GLP-1 Medications with a simple generic name of "semaglutide", "liraglutide", "tirzepatide", "dulaglutide", "exenatide", "exenatide microspheres", or "insulin degludec/liraglutide" and at least one of: A pharmaceutical class of "ANTI-OBESITY GLUCAGON-LIKE PEPTIDE-1 RECEP AGONIST" or "ANTIHYPERGLYCEMIC - INCRETIN MIMETICS COMBINATION" A pharmaceutical class that contains "GLP-1" A pharmaceutical subclass that contains the text "GLP-1"
What skin concerns can Sofwave address beyond sagging skin
Given the FDA's April 2026 proposal with a comment period closing June 29, 2026, this a real question for anyone starting a multi-month compounded GLP-1 program right now
